Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENAYA: Faricimab vs Aflibercept in Neovascular Age-related Macular Degeneration
jRCT2080224626Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of faricimab in exudative macular degeneration (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Visual acuity change at Week 48. Started Apr 2019; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2080224626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224626.